Building a business


Nature Biotechnology , 133 - 135 (2006)
Published online: 24 January 2006 | doi:10.1038/bioent899

Keeping it real with investors

Michelle Dipp1, Christoph Westphal1, Chad Mirkin2, James Baker3, Tim Harper4 & Charles Harris5


Nanobiotech entrepreneurs learned the hard way that there is such a thing as pushing so-called exotic or emerging technologies too hard with investors. Biotech entrepreneurs could learn a thing or two from their experience.

Top
  1. Michelle Dipp and Christoph Westphal are at Sirtris Pharmaceuticals, 790 Memorial Drive, Suite 104, Cambridge, Massachusetts, 02139, USA, e-mail: mdipp@sirtrispharma.com, e-mail: cwestphal@sirtrispharma.com
  2. Chad Mirkin is at International Institute for Nanotechnology at Northwestern University, 2145 Sheridan Road, Evanston, Illinois, 60208, USA, e-mail: chadnano@northwestern.edu
  3. James Baker is at the University of Michigan, Nanotechnology Institute for Medicine and the Biological Sciences (M-NIMBS), 9220 MSRB III, Ann Arbor, Michigan, 48109-0648, USA, e-mail: jbakerjr@med.umich.edu
  4. Tim Harper is at Cientifica Ltd, 7 Devonshire Square London, EC2M 4EY, UK, e-mail: tim.harper@cientifica.com
  5. Charles Harris is at Harris & Harris Group, 111 West 57th Street, Suite 1100, New York, New York, 10019, USA, e-mail: charlie@TinyTechVC.com